Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States Journal Article
| Authors: | Dawwas, G. K.; Leonard, C. E.; Garg, M.; Vouri, S. M.; Smith, S. M.; Flory, J. H.; Genuardi, M. V.; Park, H. |
| Article Title: | Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States |
| Abstract: | We conducted a cross-sectional analysis using a database from commercial health plans in the United States to describe trends in the use of antidiabetic medications among patients with type 2 diabetes and heart failure (HF) from 2006 through 2017. We used loop diuretic dose as a surrogate for HF severity (mild HF 0-40 mg/day, moderate-severe HF >40 mg/day). We assessed antidiabetic medication dispensing in the 90 days following HF diagnosis. Over the 12-year period, we identified an increase in the use of metformin (39.2% vs. 62.6%), dipeptidyl peptidase-4 inhibitors (DPP-4i) (0.5% vs. 17.1%) and sodium-glucose co-transporter-2 inhibitors (SGLT-2i) (0.0% vs. 9.0%), but a decrease in the use of sulphonylureas (47.8% vs. 27.8%) and thiazolidinediones (TZDs) (31.7% vs. 5.3%). In 2017, patients with moderate-severe HF more commonly used insulin (43.1%); a majority of mild HF patients used metformin (62.8%). A proportion of patients with moderate-severe HF used TZDs (4.4%). Among patients with diabetes and HF, the use of metformin and DPP-4i rapidly increased, but a proportion of patients with moderate-severe HF continued to use TZDs. Despite their promising cardiovascular safety profile, SGLT-2i use remains limited. © 2020 John Wiley & Sons Ltd |
| Keywords: | adult; controlled study; treatment outcome; aged; major clinical study; united states; sensitivity and specificity; incidence; retrospective study; disease severity; cardiovascular disease; heart failure; insulin; cross-sectional study; sex difference; trend study; metformin; non insulin dependent diabetes mellitus; predictive value; drug use; type 2 diabetes; pharmacoepidemiology; loop diuretic agent; 2,4 thiazolidinedione derivative; sulfonylurea; cohort study; human; male; female; article; icd-9-cm; amylin; meglitinide; alpha glucosidase inhibitor; dipeptidyl peptidase iv inhibitor; sodium glucose cotransporter 2 inhibitor; sodium-glucose co-transporter-2 inhibitor; icd-10-cm |
| Journal Title: | Diabetes, Obesity and Metabolism |
| Volume: | 22 |
| Issue: | 4 |
| ISSN: | 1462-8902 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2020-04-01 |
| Start Page: | 705 |
| End Page: | 710 |
| Language: | English |
| DOI: | 10.1111/dom.13949 |
| PUBMED: | 31903713 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 April 2020 -- Source: Scopus |
